Alpha 2.0
Login Register
» Authors » Antonius W M Boersma

Antonius W M Boersma

Explore the profile of Antonius W M Boersma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 677
Followers 0
Related Specialties
Oncology
Molecular Biology
Pharmacology
Top 10 Co-Authors
Erik A C Wiemer
Herman Burger
Marijn T M van Jaarsveld
Ron H J Mathijssen
Marcel Smid
John W M Martens
Gerrit Stoter
Kees Nooter
Mariel Brok
Jaap Verweij
Published In
Mol Pharmacol
Proc Natl Acad Sci U S A
Int J Cancer
BMC Cancer
Blood
Affiliations
Soon will be listed here.
Recent Articles
11.
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
Burger H, van Tol H, Boersma A, Brok M, Wiemer E, Stoter G, et al.
Blood . 2004 Jul; 104(9):2940-2. PMID: 15251980
Imatinib mesylate (STI571), a potent tyrosine kinase inhibitor, is successfully used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. However, the intended chronic oral administration of imatinib...
12.
Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill
Schenk P, Brok M, Boersma A, Brandsma J, den Dulk H, Burger H, et al.
Mol Pharmacol . 2003 Jul; 64(2):259-68. PMID: 12869630
The therapeutic potential of antitumor drugs is seriously limited by the manifestation of cellular drug resistance. We used the budding yeast Saccharomyces cerevisiae as a model system to identify novel...
13.
Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype
Schenk P, Boersma A, Brok M, Burger H, Stoter G, Nooter K
Mol Pharmacol . 2002 Feb; 61(3):659-66. PMID: 11854447
The therapeutic potential of the highly active anticancer agent cisplatin is severely limited by the occurrence of cellular resistance. A better understanding of the molecular pathways involved in cisplatin-induced cell...